A cost-effectiveness analysis model of actionable genomic alteration testing strategies incorporating different modalities and sizes of next-generation sequencing panels in non-small-cell lung cancer

In our high EGFR-mutation prevalence population, exclusionary plasma EGFR followed by medium panel tissue NGS was cost-effective. Our analysis provides insight on NGS testing strategies of different gene panel sizes and sample types.